首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2205篇
  免费   246篇
  国内免费   22篇
耳鼻咽喉   24篇
儿科学   77篇
妇产科学   43篇
基础医学   157篇
口腔科学   93篇
临床医学   265篇
内科学   451篇
皮肤病学   117篇
神经病学   125篇
特种医学   161篇
外科学   416篇
综合类   125篇
现状与发展   30篇
预防医学   146篇
眼科学   26篇
药学   101篇
中国医学   5篇
肿瘤学   111篇
  2024年   18篇
  2023年   188篇
  2022年   43篇
  2021年   51篇
  2020年   80篇
  2019年   51篇
  2018年   90篇
  2017年   76篇
  2016年   63篇
  2015年   85篇
  2014年   138篇
  2013年   108篇
  2012年   94篇
  2011年   93篇
  2010年   117篇
  2009年   115篇
  2008年   69篇
  2007年   90篇
  2006年   57篇
  2005年   54篇
  2004年   45篇
  2003年   41篇
  2002年   42篇
  2001年   26篇
  2000年   27篇
  1999年   44篇
  1998年   42篇
  1997年   53篇
  1996年   46篇
  1995年   42篇
  1994年   34篇
  1993年   37篇
  1992年   15篇
  1991年   21篇
  1990年   14篇
  1989年   37篇
  1988年   26篇
  1987年   33篇
  1986年   12篇
  1985年   25篇
  1984年   12篇
  1983年   5篇
  1982年   12篇
  1981年   16篇
  1980年   15篇
  1978年   9篇
  1976年   13篇
  1975年   12篇
  1974年   5篇
  1966年   4篇
排序方式: 共有2473条查询结果,搜索用时 15 毫秒
91.
Noma neonatorum should be differentiated from noma, in that it is typically a disease of seriously ill premature infants whose birth weight was low, and is caused by Pseudomonas aerugenosa septicaemia. We know of only two case reports of noma neonatorum involving newborn infants born at full term, so we report here another case of noma neonatorum in a neonate born at full term. In addition we describe the differences between noma neonatorum and noma (cancrum oris), a clinically related entity.  相似文献   
92.
Catechol-O-methyltransferase (COMT) plays an important role in the catabolism of brain dopamine and norepinephrine, which have been implicated in the pathogenesis of Autism spectrum disorder (ASD) as well as in other neuropsychatric disorders. We aimed to investigate the association of COMT Val158Met gene polymorphism with ASD and to examine the influence of such genotypes on hyperactivity symptoms in ASD patients. Eighty ASD patients (mean age 9 ± 1.9 years) and 100 control children (mean age 8.9 ± 1.9 years) were examined. COMT Val58Met polymorphism was genotyped using Tetra-primer ARMS-PCR method. The clinical diagnosis of ASD and ADHD were confirmed according to the DSM-IV criteria for research. We found no significant difference in genotypes or alleles’ frequencies of COMT Val158Met polymorphism between ASD patients and control group. There was a significant association between COMT (Val/Val) genotype and both increasing CARS (p = 0.001) and hyperactivity scores (p = 0.006). Regarding Conner's Score, the DSM-IV hyperactive impulsive were significantly higher in Val/Val genotype than both Met/Val and Met/Met genotypes (p = 0.03). Our data suggested an association between COMT Val58Met polymorphism and hyperactivity symptoms in Egyptian children with ASD.  相似文献   
93.
94.
95.
96.
97.

Background

Late or inadequate therapeutic management increases the risk of mortality associated with HIV/AIDS. The aim of this study was to analyze the proportion and factors associated with loss of follow-up in HIV patients who receiving antiretroviral therapy at Conakry.

Methods

A retrospective cohort study was conducted in HIV patients aged over 15 years and who receiving antiretroviral therapy. Between August 1, 2008 and July 31, 2015, all patients managed by the ambulatory treatment center of the Guinean Women Association against AIDS and sexually and transmissible infection were included. Loss of follow-up was defined as no follow-up visit within 3 months. Kaplan–Meier curves and multivariate Cox regression models were used to analyze factors associated with loss of follow-up. Analyses were performed by using Stata 13 software.

Results

614 patients aged 36.3 ± 11.2 years, mainly females (68.4%) and living in Conakry (80.5%) were included. Among them, 104 were loss to follow-up, corresponding to a proportion rate of 16.9% (95% CI: 14.2–19.7%) or 5.79/100 person-years. The results of multivariate analyses showed that factors independently associated with loss of follow-up were malnutrition (AHR = 7.05; 95% CI: 2.05–24.27; P = 0.002) and CD4 cells account at the initiation of AHR (2.35; 95% CI: 1.61–6.39; P = 0.016) in patients with 201–350 CD4/μL and 5.83 (95% CI: 2.85–11.90; P < 0.001) in patients with less than 150 CD4/μL.

Conclusion

Despite efforts of health care workers and free antiretroviral therapy, many patients were loss to follow-up. Multivariate analysis showed that malnutrition and low CD4 account were independently associated with loss to follow-up.  相似文献   
98.

Background

In previous studies, correlation between overall survival (OS) and surrogate endpoints like objective response rate (ORR) or progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) was poor. This can be biased by crossover and postprogression treatments.

Objectives

To evaluate the relationship between these two surrogate endpoints and OS in advanced NSCLC studies that did not allow for crossover or reported balanced post-progression treatments.

Methods

A systematic review in patients with advanced NSCLC receiving second- and further-line therapy was performed. The relationship between the absolute difference in ORR or median PFS (mPFS) and the absolute difference in median OS (mOS) was assessed using the correlation coefficient (R) and weighted regression models. The analysis was repeated in predefined data cuts based on crossover and balance of postprogression treatments. When the upper limit of R’s 95% confidence interval (CI) was more than 0.7, the surrogate threshold effect (STE) was estimated.

Results

In total, 146 randomized clinical trials (43,061 patients) were included. The mean ORR, mPFS, and mOS were 12.2% ± 11.2%, 3.2 ± 1.3 months, and 9.6 ± 4.1 months, respectively. The correlation coefficients of ORR and mPFS were 0.181 (95% CI 0.016–0.337) and 0.254 (95% CI 0.074–0.418), respectively, with mOS. Nevertheless, in trials that did not allow crossover and reported balanced postprogression treatments, the correlation coefficients of ORR and mPFS were 0.528 (95% CI 0.081–0.798) and 0.778 (95% CI 0.475–0.916), respectively, with mOS. On the basis of STE estimation, in trials showing significant treatment effect size of 41.0% or more ORR or 4.15 or more mPFS months, OS benefit can be expected with sufficient certainty.

Conclusions

Crossover and postprogression treatments may bias the relationship between surrogate endpoints and OS. Presented STE calculation can be used to interpret treatment effect on either ORR or PFS when used as primary endpoints.  相似文献   
99.
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号